Brevan Howard Capital Management LP
Position in KYTX — Kyverna Therapeutics, Inc.
CIK 1512857
ST. HELIER, Y9
Position in KYTX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
-$284,045 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
2 quarters on record
Derivatives in KYTX
reported options exposure · as of Mar 31, 2026CallValue
$548,143
CallShares
63,516
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Brevan Howard Capital Management LP holds $135,260,176 across 173 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
81,570 | $6,057,388 | |
| 2 | ASND |
Ascendis Pharma A/S
|
26,200 | $5,992,726 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
204,845 | $4,785,179 | |
| 4 | TERN |
Terns Pharmaceuticals, Inc.
|
88,596 | $4,670,780 | |
| 5 | MRNA |
Moderna, Inc.
|
89,594 | $4,551,375 | |
| 6 | SLNO |
Soleno Therapeutics Inc
|
135,621 | $4,540,590 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
215,845 | $4,521,951 | |
| 8 | INCY |
Incyte Corp
|
46,448 | $4,371,685 |
All Filings in KYTX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $548,143 | 63,516 | Call | Defined | 2026-05-15 | |
| 2024-03-31 | $284,045 | 11,435 | Shares | Defined | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||